Conference reports

Vaping can help HIV positive smokers who are not motivated to quit cigarettes

IDWeek (2019), 2–6 October 2019, Washington DC

HIV suppression and safety with ibalizumab at 48 weeks in expanded access

Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study

Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available

Switching from TDF to TAF linked to higher BMI and cardio risk

Possible higher diabetes risk with raltegravir or PIs than NNRTIs

Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives

Over half of mostly black US HIV group has NAFLD – and many have NASH

People taking more medications and women have higher fall risk in older HIV group

No link between raltegravir and adverse birth outcomes in analysis in 2550 women

PrEP linked to lower HIV incidence in US, independent of TasP

10th IAS Conference on HIV Science (IAS 2019): final reports

Low rates of pregnancy with three methods of contraception in the ECHO trial

Other pregnancy studies IAS 2019

10th IAS Conference on HIV Science (IAS 2019) in Mexico City

Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

Dolutegravir for younger children: results from the ODYSSEY trial

PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study

10th IAS Conference on HIV Science (IAS 2019) in Mexico City

Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals

WHO recommends dolutegravir-based ART regimens for all

High rates of viral suppression with low dose efavirenz in pregnant Zambian women

First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10

Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results

Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy

Fostemsavir: 96-week follow-up in people with multi-drug resistance

Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96

Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study

Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year

Upcoming 10th IAS Conference on HIV Science (IAS 2019)

IAS 2019: late breaker highlights to look for

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs

Efavirenz 600 mg exposure appears sufficient with high-dose daily rifapentine

Drug-drug interactions between efavirenz and levonorgestrel influenced by genetic variants 

Infant dolutegravir exposure through placental and breastmilk transfer  

Antiretroviral pharmacokinetics in pregnancy: update from IMPAACT P1026s

13th INTEREST workshop 14–17 May 2019, Accra, Ghana

No increased adverse outcomes among women starting dolutegravir before conception in the ADVANCE study

25th Annual BHIVA Conference (BHIVA 2019)

Fifty new HIV diagnoses at Dean Street linked to caps on IMPACT study

Management of testosterone deficiency in HIV positive people

Importance of including menopause and bone health in management of HIV positive women

Type 2 diabetes is often undermanaged in HIV positive people

Adopting new US blood pressure targets for HIV positive people could reduce cardiovascular-related deaths

Selected webcasts from BHIVA 2019

Conference on Retroviruses and Opportunistic Infections (CROI 2019) 4–7 March, 2019

INSTI and weight gain: reports from CROI 2019

B/F/TAF suitable for children from six years of age

25th Annual BHIVA Conference (BHIVA 2019)

BHIVA preconference: U=U and HIV and immigration detention

Conference on Retroviruses and Opportunistic Infections (CROI 2019): third reports

bNAb research at CROI 2019: vaccine, prevention, treatment and cure…

Paediatric dolutegravir update

Other cure related studies at CROI 2019

Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports

Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10

Capsid inhibitor GS-6207 shows potential for 3-monthly injections

First phase 1 results from bNAb PGT121 in HIV positive people

Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies

Same-day ART is effective in San Francisco Rapid-ART clinic

Integrase inhibitors and neural tube defects: more data still needed

Double-dose levonorgestrel implant does not overcome interaction with efavirenz

Post navigation